Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

TThis is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

alt text

We would love to know your plans on using a contract organisation to support Formulation Development.

Please let us know your thoughts before accessing the on demand webinar. 

Whether via the eye, skin, lungs, nose, or mucosal membranes these alternative routes offer key advantages alongside presenting unique challenges.  To ensure a patient centric approach, pharmaceutical product developers are increasingly looking away from traditional routes of delivery and dosage forms (solid oral, intravenous).

The key to accelerating development in this area is the use of viable relevant human tissue in vitro models to optimize the drug or drug product to de-risk clinical trial and investment decisions. These models provide a measure of biological efficacy prior to the clinic and without translational concerns from animal models.

During this webinar you will learn about:

  • The challenges and opportunities of targeting these routes of delivery
  • Approaches to de-risk product development to boost chances of success
  • The latest advances in in vitro models based on human tissue to create meaningful data investors and regulators trust
  • Case Studies: Where these models have been used to significantly influence programs and ensure success


alt text

Dr Jon Lenn

Chief Technology Officer

Jon Lenn has direct responsibility for MedPharm’s pharmaceutical innovation and technology strategies and is based out of its facility in Durham, North Carolina.

Since founding MedPharm’s US operations in 2015 he has led the development of cutting-edge biological models, novel test systems, and the use of automation and robotics to streamline and enhance the drug development process. He has over 15 years’ experience within the Pharmaceutical industry developing topical medications from early discovery through development and into post-marketing support with companies such as Connetics, Stiefel and GlaxoSmithKline where he was directly involved with the development and approval of 8 marketed products.

Jon has spent the last several years in the development, optimization, qualification, and validation of novel biological models and testing tools to support the development of high quality medicines for topical and transdermals (including skin, nail, airways, mucosal membranes and the eye). He received his PhD on the topical delivery of macromolecules from the University of Reading.

Moderated by

Maire Gerrard

Custom Content Writer

Informa Pharma Intelligence

Complete the form to access the webinar on demand!

Do you expect to use a contract organization to support the Formulation Development of any products you are targeting for non-traditional routes of delivery?

To learn more about MedPharm please click here.

By completing this form you agree MedPharm may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.